Medizinische Universität Graz - Research portal
Selected Publication:
Pickel, H; Petru, E; Lahousen, M; Stettner, H; Lehnert, M.
Efficacy of adjuvant carboplatin-epirubicin chemotherapy in advanced ovarian cancer after radical surgery.
Oncology. 1989; 46(4):222-225
Doi: 10.1159/000226720
Web of Science
PubMed
FullText
FullText_MUG
Google Scholar
- Co-authors Med Uni Graz
- Lahousen Manfred
- Petru Edgar
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Postoperatively, 13 patients with stage III ovarian cancer received a combination of carboplatin and epirubicin (PE) at 300 and 60 mg/m2 respectively. The results of the 13 patients receiving the PE regimen were retrospectively compared to those of 24 patients who received the conventional PAC schedule (cisplatin, Adriamycin and cyclophosphamide at a dosage of 50, 50 and 750 mg/m2, respectively). All 37 patients had undergone radical debulking surgery including pelvic and paraaortic lymphadenectomy. At 8 months, relapse-free rates of 42.2 and 79.2% were observed in the PE and PAC groups, respectively. This difference was highly significant (p = 0.011). The data suggest that the PE combination has less antineoplastic activity than the PAC schedule and thus cannot be recommended in the adjuvant treatment of advanced ovarian cancer.
- Find related publications in this database (using NLM MeSH Indexing)
- Adult -
- Aged -
- Antineoplastic Combined Chemotherapy Protocols - adverse effects
- Carboplatin - adverse effects
- Cisplatin - administration and dosage
- Combined Modality Therapy - administration and dosage
- Cyclophosphamide - administration and dosage
- Doxorubicin - administration and dosage
- Epirubicin - administration and dosage
- Female - administration and dosage
- Humans - administration and dosage
- Middle Aged - administration and dosage
- Organoplatinum Compounds - administration and dosage
- Ovarian Neoplasms - drug therapy
- Retrospective Studies - drug therapy